Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Videos

Quadricuspid Aortic Valve

Cholanahalli Nanjappa Manjunath, MD, DM
Akash Jain, MD
Jayashree Kharge, MD, DM
Yamasandi Siddegowda Shrimanth, MD, DM
08/28/2023
Video 1. Cardiac magnetic resonance imaging cine in the oblique axial plane at the aortic root shows Type B quadricuspid aortic valve with 3 equal-sized cusps and 1 smaller cusp (arrow), along with 4 sinuses. Incomplete closure of the aortic valve is also seen during diastole, causing aortic regurgitation.
Video 2. Cardiac magnetic resonance imaging cine in the oblique coronal view through the aortic valve and left ventricular outflow tract shows severe aortic regurgitation.

Video Supplement to "Quadricuspid Aortic Valve" (September 2023 Case Report).

A 56-year-old man presented with typical angina for 1 day and a prior history of exertional  dyspnea of 6 months duration. Clinically, he was diagnosed with severe aortic regurgitation (AR). Electrocardiogram showed left ventricular hypertrophy with volume overload. Transthoracic echocardiography (TTE) showed severe AR with mild left ventricular dysfunction. Although aortic valve morphology appeared to be quadricuspid, it was not clear on TTE. In view of elevated troponin levels, a coronary angiogram was done that showed 90% stenosis in the proximal left anterior descending artery. 

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of INSERT BRAND or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

News

DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest
Intravascular Lithotripsy
Data From Elixir’s PINNACLE I Trial for Calcium Fragmentation in Calcified Coronary Artery Lesions Presented at TCT
10/30/2024
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging...
10/30/2024
Cath Lab Digest
Tricuspid Valve Treatment
TCT: TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
10/30/2024
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized...
10/30/2024
Cath Lab Digest
Post MI
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
10/30/2024
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in...
10/30/2024
Cath Lab Digest
Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest
Large Bore Closure
TCT: Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal Large Hole Closure Device
10/29/2024
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure Device System (PerQSeal) is the first sutureless, fully absorbable synthetic implement for large-bore vessel punctures, and is an alternative to the use of suture- or collagen-based closure devices.
The Vivasure PerQseal® Closure...
10/29/2024
Cath Lab Digest

Advertisement

Advertisement

TAVR
TAVR UNLOAD @TCT: Transcatheter Aortic Valve Replacement in Patients with Systolic Heart Failure and Moderate Aortic Stenosis Shows Limited Benefits
10/30/2024
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings from the TAVR UNLOAD...
10/30/2024
Cath Lab Digest
DCB
SIRONA Trial @TCT – First Head-to-Head Comparison of Sirolimus Versus Paclitaxel DCBs in the Treatment of PAD: Sirolimus-Coated Balloons Yield Similar Results to Paclitaxel-Coated Balloons in the Femoropopliteal Artery
10/30/2024
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective, multicenter, investigator-initiated SIRONA randomized clinical trial demonstrated MagicTouch™️ sirolimus-coated balloons to be noninferior compared to paclitaxel-coated balloons with regards to the primary safety...
Data from the prospective,...
10/30/2024
Cath Lab Digest
acute mI
CLEAR SYNERGY (OASIS 9) Trial @TCT: Routine Colchicine Administration After Acute Myocardial Infarction Does Not Improve Outcomes
10/30/2024
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication that reduces inflammation and smaller studies have indicated potential benefits for cardiovascular patients.
Colchicine is an oral medication...
10/30/2024
Cath Lab Digest
Intravascular Lithotripsy
Data From Elixir’s PINNACLE I Trial for Calcium Fragmentation in Calcified Coronary Artery Lesions Presented at TCT
10/30/2024
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging sub-study using optical coherence tomography (OCT) was conducted to accurately assess lesion complexity and calcium fragmentation effectiveness of LithiX IVL across a range of complex calcium morphologies.
An intravascular imaging...
10/30/2024
Cath Lab Digest
Tricuspid Valve Treatment
TCT: TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-Life Benefits With Edwards Evoque System for Severe Tricuspid Regurgitation
10/30/2024
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized controlled pivotal trial designed to study the Evoque transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to OMT alone with 2:1 randomization.
TRISCEND II is a randomized...
10/30/2024
Cath Lab Digest
Post MI
After a Heart Attack, the Heart Signals to the Brain to Increase Sleep to Promote Healing
10/30/2024
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in Nature, emphasize the importance of increased sleep after a heart attack, and suggest that sufficient sleep should be a focus of post-heart-attack clinical management and care, including in the intensive care...
The novel findings, published in...
10/30/2024
Cath Lab Digest
Bioadaptors
TCT: DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
10/29/2024
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant benefit of the DynamX® Coronary Bioadaptor System compared to a contemporary zotarolimus drug-eluting stent for target lesion failure in complex patient population subsets from the INFINITY-SWEDEHEART RCT.
Data demonstrate significant...
10/29/2024
Cath Lab Digest
Aortic Stenosis
TCT: Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)
10/29/2024
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from over 2 million patients in a real-world database of 29 teaching and non-teaching U.S. health systems.
The study analyzed data from...
10/29/2024
Cath Lab Digest
Zilver Vena Stent
Zilver Vena Stent Shows High Patency Across All Patient Groups in Three-Year Clinical Study
10/29/2024
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook Medical’s Zilver Vena® Venous Self-Expanding Stent has shown high rates of patency sustained for three years, according to recently published data in the Journal of Vascular and Interventional Radiology (JVIR).1 The...
Bloomington, Ind. — Cook...
10/29/2024
Vascular Disease Management
Coronary Atherectomy
TCT: Treating Severe Calcification With an Atherectomy Device Does Not Improve Cardiac Stenting Outcomes, ECLIPSE Study Finds
10/29/2024
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy may be reserved for the most extreme cases for which the operator does not believe that balloon angioplasty would be likely to safely cross or pre-dilate the calcified lesion,” said Gregg Stone, MD.
"The use of orbital atherectomy...
10/29/2024
Cath Lab Digest

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement